康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

INSIDE INFORMATION RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION APPROVED FOR EMERGENCY USE IN INDONESIA
INSIDE INFORMATION UPDATES ON 2022 PRELIMINARY ANNUAL RESULTS
DISCLOSEABLE TRANSACTION PURCHASE OF STRUCTURED DEPOSIT
DISCLOSEABLE TRANSACTION PURCHASE OF STRUCTURED DEPOSIT
Monthly Return of Equity Issuer on Movements in Securities
INSIDE INFORMATION - RESULTS FORECAST FOR THE YEAR 2022
DISCLOSEABLE TRANSACTION PURCHASE OF STRUCTURED DEPOSIT
INSIDE INFORMATION - INTENTION TO ISSUE GLOBAL DEPOSITORY RECEIPTS AND APPLY FOR ADMISSION TO LISTING ON SIX SWISS EXCHANGE AG
VOLUNTARY ANNOUNCEMENT -CLINICAL RESEARCH RESULTS OF A CLINICAL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF HETEROLOGOUS BOOSTING WITH COVID-19 MRNA VACCINE
Monthly Return of Equity Issuer on Movements in Securities

1 19 20 21 22 23 52